The SGLT2 Inhibitor Empagliflozin Exerts Neuroprotective Effect Against Hydrogen Peroxide-induced Toxicity on Primary Neurons

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2024 Nov 19

PMID 39560812

Authors

Athena S Davri

Andreas P Katsenos

Guzal K Tulyaganova

Nikolaos P Tzavellas

Yannis V Simos

Foivos S Kanellos

Spyridon Konitsiotis

Evangelia Dounousi

Konstantina Niaka

Sofia Bellou

Panagiotis Lekkas

Chryssa Bekiari

Anna Batistatou

Dimitrios Peschos

Konstantinos I Tsamis

Affiliations

Soon will be listed here.

Abstract

Oxidative stress has been implicated in several chronic pathological conditions, leading to cell death and injury. Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) have several overlapping mechanisms as they are both characterized by increased oxidative stress, inflammation, insulin resistance, and autophagy dysfunction. The objective of this study was to elucidate the possible neuroprotective effect of empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), against hydrogen peroxide-induced neurotoxicity in primary hippocampal neurons derived from wild-type (WT) and transgenic AD rats (TgF344-AD). An in vitro oxidative stress model was established using hydrogen peroxide to induce damage to neurons. Empagliflozin pretreatment was tested on this model initially through a cell viability assay. Flow cytometry and cell sorting were employed to discriminate the apoptotic and necrotic neuronal cell populations. Finally, the morphological and morphometric features of the neurons, including dendritic length and spine density, were evaluated using the SNT ImageJ plug-in following immunostaining with GFP. Sholl analysis was used to evaluate the impact of empagliflozin and hydrogen peroxide on dendritic arborization. Empagliflozin tended to ameliorate hydrogen peroxide-induced toxicity in primary neurons derived from WT rats and led to the preservation of dendritic spine density in both WT and TgF344-AD neurons (one-way ANOVA, p < 0.05). A modest improvement in dendrites' length was also observed. Empagliflozin pretreatment can partially mitigate dendritic and spine alterations induced by hydrogen peroxide in primary neurons. These results underscore the impact of empagliflozin on neuronal morphology and highlight its potential as a candidate for the treatment and/or prevention of AD.

References

Abdel-Latif R, Rifaai R, Amin E . Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch Pharm Res. 2020; 43(5):514-525. DOI: 10.1007/s12272-020-01237-y. View

Abdul-Ghani M, Norton L, DeFronzo R . Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. DOI: 10.1210/er.2010-0029. View

Al Hamed F, Elewa H . Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. Clin Ther. 2020; 42(11):e242-e249. DOI: 10.1016/j.clinthera.2020.09.008. View

Beaudoin 3rd G, Lee S, Singh D, Yuan Y, Ng Y, Reichardt L . Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc. 2012; 7(9):1741-54. DOI: 10.1038/nprot.2012.099. View

Butterfield D, Halliwell B . Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019; 20(3):148-160. PMC: 9382875. DOI: 10.1038/s41583-019-0132-6. View

Chiba Y, Sugiyama Y, Nishi N, Nonaka W, Murakami R, Ueno M . Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains. Neuropathology. 2020; 40(5):482-491. PMC: 7587001. DOI: 10.1111/neup.12665. View

Cochran J, Hall A, Roberson E . The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull. 2013; 103:18-28. PMC: 3989444. DOI: 10.1016/j.brainresbull.2013.12.004. View

Flannery P, Trushina E . Mitochondrial dynamics and transport in Alzheimer's disease. Mol Cell Neurosci. 2019; 98:109-120. PMC: 6614006. DOI: 10.1016/j.mcn.2019.06.009. View

Horner C, Arbuthnott E . Methods of estimation of spine density--are spines evenly distributed throughout the dendritic field?. J Anat. 1991; 177:179-84. PMC: 1260425. View

10.

Jantas D, Chwastek J, Malarz J, Stojakowska A, Lason W . Neuroprotective Effects of Methyl Caffeate against Hydrogen Peroxide-Induced Cell Damage: Involvement of Caspase 3 and Cathepsin D Inhibition. Biomolecules. 2020; 10(11). PMC: 7696984. DOI: 10.3390/biom10111530. View

11.

Katsenos A, Davri A, Simos Y, Nikas I, Bekiari C, Paschou S . New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opin Investig Drugs. 2021; 31(1):105-123. DOI: 10.1080/13543784.2022.2022122. View

12.

Kowianski P, Lietzau G, Czuba E, Waskow M, Steliga A, Morys J . BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol Neurobiol. 2017; 38(3):579-593. PMC: 5835061. DOI: 10.1007/s10571-017-0510-4. View

13.

Lopez O, Kuller L . Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. Handb Clin Neurol. 2019; 167:139-148. DOI: 10.1016/B978-0-12-804766-8.00009-1. View

14.

Michailidis M, Tata D, Moraitou D, Kavvadas D, Karachrysafi S, Papamitsou T . Antidiabetic Drugs in the Treatment of Alzheimer's Disease. Int J Mol Sci. 2022; 23(9). PMC: 9102472. DOI: 10.3390/ijms23094641. View

15.

Mijalkov M, Volpe G, Fernaud-Espinosa I, DeFelipe J, Pereira J, Merino-Serrais P . Dendritic spines are lost in clusters in Alzheimer's disease. Sci Rep. 2021; 11(1):12350. PMC: 8196005. DOI: 10.1038/s41598-021-91726-x. View

16.

Navale A, Paranjape A . Glucose transporters: physiological and pathological roles. Biophys Rev. 2017; 8(1):5-9. PMC: 5425736. DOI: 10.1007/s12551-015-0186-2. View

17.

Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj E . Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001; 60(8):759-67. DOI: 10.1093/jnen/60.8.759. View

18.

Pang B, Zhang L, Li B, Sun F, Wang Z . The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. Physiol Behav. 2023; 263:114134. DOI: 10.1016/j.physbeh.2023.114134. View

19.

Pawlos A, Broncel M, Wozniak E, Gorzelak-Pabis P . Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021; 26(23). PMC: 8659196. DOI: 10.3390/molecules26237213. View

20.

Pemberton K, Mersman B, Xu F . Using ImageJ to Assess Neurite Outgrowth in Mammalian Cell Cultures: Research Data Quantification Exercises in Undergraduate Neuroscience Lab. J Undergrad Neurosci Educ. 2018; 16(2):A186-A194. PMC: 6057772. View